SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Iovance Biotherapeutics, Inc. – ‘8-K’ for 4/9/21

On:  Monday, 4/12/21, at 4:10pm ET   ·   For:  4/9/21   ·   Accession #:  1104659-21-49327   ·   File #:  1-36860

Previous ‘8-K’:  ‘8-K’ on / for 3/15/21   ·   Next:  ‘8-K’ on 4/26/21 for 4/20/21   ·   Latest:  ‘8-K’ on / for 3/4/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/12/21  Iovance Biotherapeutics, Inc.     8-K:8,9     4/09/21   12:9.7M                                   Toppan Merrill/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     29K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     59K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     21K 
 8: R1          Cover                                               HTML     48K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- tm2112731d1_8k_htm                  XML     15K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 5: EX-101.LAB  XBRL Labels -- iova-20210409_lab                     XML     97K 
 6: EX-101.PRE  XBRL Presentations -- iova-20210409_pre              XML     64K 
 4: EX-101.SCH  XBRL Schema -- iova-20210409                         XSD     13K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    33K 
12: ZIP         XBRL Zipped Folder -- 0001104659-21-049327-xbrl      Zip     32K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:   C:   C:   C:   C:   C:   C:   C: 
 i 0001425205  i false 0001425205 2021-04-09 2021-04-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM  i 8-K
Current Report

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported):  i April 9, 2021

 

 i IOVANCE BIOTHERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 i Delaware
(State of Incorporation)
 
 i 001-36860    i 75-3254381
Commission File Number   (I.R.S. Employer Identification No.)
     
 i 999 Skyway Road,  i Suite 150    
 i San Carlos,  i California    i 94070
(Address of Principal Executive Offices)   (Zip Code)
     
( i 650)  i 260-7120
(Registrant’s Telephone Number, Including Area Code)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 i ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

 i ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

 i ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

 i ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  i ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
 i Common stock, par value $0.000041666 per value  i IOVA  i The Nasdaq Stock Market, LLC

 

 

 

 C: 

 

 

 

Item 8.01 Other Events.

 

On April 12, 2021, Iovance Biotherapeutics, Inc. (the “Company”) updated its corporate slide deck that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company’s presentation that it intends to use at such events is attached as Exhibit 99.1 and incorporated herein by reference.

 

On April 9, 2021, the Company issued a press release announcing updated clinical data from Cohort 2 in its C-144-01 study of lifileucel in advanced melanoma, which will be part of an oral presentation in a clinical trials plenary session at the American Association for Cancer Research (AACR) 2021 Annual Meeting. The full text of the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)       Exhibits.

 

Exhibit No.   Description
99.1   Iovance Biotherapeutics, Inc., Corporate Presentation – April 2021.
99.2   Press Release of Iovance Biotherapeutics, Inc., dated April 9, 2021.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 12, 2021 IOVANCE BIOTHERAPEUTICS, INC.
     
  By: /s/ MARIA FARDIS
    Maria Fardis, Chief Executive Officer

 

 C: 

 

 

 C: 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:4/12/21None on these Dates
For Period end:4/9/21
 List all Filings 
Top
Filing Submission 0001104659-21-049327   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 6:17:48.1pm ET